Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial

Trial Profile

Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin; Raltitrexed
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Acronyms BRANCH
  • Most Recent Events

    • 27 Nov 2015 Planned End Date changed from 1 Jan 2014 to 1 Mar 2017 as reported by ClinicalTrials.gov
    • 27 Nov 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 03 Dec 2011 Planned number of patients changed from 46 to NULL.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top